HomeCompareORINF vs NNN

ORINF vs NNN: Dividend Comparison 2026

ORINF yields 2.71% · NNN yields 5.68%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORINF wins by $1.1K in total portfolio value
10 years
ORINF
ORINF
● Live price
2.71%
Share price
$78.95
Annual div
$2.14
5Y div CAGR
9.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.6K
Annual income
$871.03
Full ORINF calculator →
NNN
NNN REIT Inc.
● Live price
5.68%
Share price
$41.89
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$2,637.42
Full NNN calculator →

Portfolio growth — ORINF vs NNN

📍 ORINF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORINFNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORINF + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORINF pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORINF
Annual income on $10K today (after 15% tax)
$230.40/yr
After 10yr DRIP, annual income (after tax)
$740.38/yr
NNN
Annual income on $10K today (after 15% tax)
$482.93/yr
After 10yr DRIP, annual income (after tax)
$2,241.81/yr
At 15% tax rate, NNN beats the other by $1,501.43/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORINF + NNN for your $10,000?

ORINF: 50%NNN: 50%
100% NNN50/50100% ORINF
Portfolio after 10yr
$26.1K
Annual income
$1,754.23/yr
Blended yield
6.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

ORINF
No analyst data
Altman Z
11.2
Piotroski
7/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+7.3% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORINF buys
0
NNN buys
0
No recent congressional trades found for ORINF or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORINFNNN
Forward yield2.71%5.68%
Annual dividend / share$2.14$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR9.4%8.6%
Portfolio after 10y$26.6K$25.6K
Annual income after 10y$871.03$2,637.42
Total dividends collected$5.4K$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ORINF vs NNN ($10,000, DRIP)

YearORINF PortfolioORINF Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$10,997$296.54$10,737$617.02+$260.00ORINF
2$12,100$333.40$11,577$710.93+$523.00ORINF
3$13,322$375.08$12,538$822.59+$784.00ORINF
4$14,676$422.22$13,645$956.06+$1.0KORINF
5$16,179$475.59$14,925$1,116.51+$1.3KORINF
6$17,848$536.06$16,415$1,310.57+$1.4KORINF
7$19,702$604.60$18,158$1,546.77+$1.5KORINF
8$21,764$682.38$20,213$1,836.20+$1.6KORINF
9$24,058$770.69$22,649$2,193.37+$1.4KORINF
10$26,613$871.03$25,558$2,637.42+$1.1KORINF

ORINF vs NNN: Complete Analysis 2026

ORINFStock

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Full ORINF Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this ORINF vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORINF vs SCHDORINF vs JEPIORINF vs OORINF vs KOORINF vs MAINORINF vs ADCORINF vs EPRTORINF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.